Paper Details

  1. Home
  2. Paper Details

Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.

Author: DingemanseJasper, KrauseAndreas, ZisowskyJochen

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.

Overview

Macitentan, an endothelin receptor antagonist, was found to be effective in treating pulmonary arterial hypertension, with higher concentrations associated with improved hemodynamics.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Macitentan is the first endothelin receptor antagonist with demonstrated efficacy on morbidity and mortality in pulmonary arterial hypertension (PAH) in the pivotal study SERAPHIN. METHODS: The pharmacokinetics (PK) of macitentan and its active metabolite, ACT-132577, were characterized...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.pupt.2018.02.005

データ提供：米国国立医学図書館（NLM）

Modeling Macitentan: Navigating the Desert of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH), a rare but serious condition affecting the arteries of the lungs, can feel like a relentless desert trek. This study delves into the world of macitentan, a medication used to treat PAH, analyzing its pharmacokinetics, efficacy, and impact on blood flow (hemodynamics). The researchers created a mathematical model to understand how macitentan works in the body and its effectiveness in treating PAH.

Charting the Path: Modeling Macitentan's Journey Through the Body

The study created a model to predict the behavior of macitentan in patients with PAH, providing valuable insights into its effectiveness and potential side effects. This model is like a map guiding travelers through the complex terrain of PAH, helping to predict the best path for treatment.

Hope on the Horizon: Macitentan's Promise for PAH Treatment

This research provides a deeper understanding of macitentan's effectiveness in treating PAH, offering hope for patients facing this challenging condition. The study also highlights the potential of using mathematical models to guide drug development and personalize treatment approaches. Just as a caravan relies on a skilled navigator to safely cross the desert, so too do patients with PAH benefit from the precision and insights provided by these models.

Dr.Camel's Conclusion

Pulmonary arterial hypertension is a demanding condition, but research continues to offer new solutions. This study provides valuable insights into the effectiveness and safety of macitentan, a medication used to treat PAH. The use of mathematical models to understand drug behavior is a powerful tool, offering hope for a brighter future for patients facing this challenging condition.

Date :
  1. Date Completed 2019-04-24
  2. Date Revised 2019-09-17
Further Info :

Pubmed ID

29501590

DOI: Digital Object Identifier

10.1016/j.pupt.2018.02.005

Related Literature

Article Analysis
・Effects of aprocitentan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.